Symbol
| FANCC
| contributors: mct/npt/pgu - updated : 05-10-2022
|
HGNC name
| Fanconi anemia, complementation group C
|
HGNC id
| 3584
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
| loss of function
|
in leukemias | tumoral
|  
|  
| --low
|  
|
by hypermethylation of promoter regions in sporadic acute leukaemia | constitutional
|  
|  
|  
| loss of function
|
associated with failure to inhibit late firing replication origins after DNA cross-linking | constitutional
|  
|  
|  
| loss of function
|
facilitates short telomere-initiated telomere recombination | tumoral
|  
|  
| --low
|  
|
in bladder cancer | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| alterations of FANCC and PTCH1 could be used as molecular marker for early diagnosis and prognosis of head and neck squamous cell carcinoma (HNSCC) | Therapy target
| introducing expression cassettes for TT-adapted U1 snRNAs into primary FANCC patient fibroblasts allowed the correction of the DNA-damage-induced G2 cell-cycle arrest in these cells, thus representing an alternative transcript-targeting approach for genetic therapy of inherited splice-site mutations |
| |